Wall Street analysts expect Karyopharm Therapeutics Inc (NASDAQ:KPTI) to announce $130,000.00 in sales for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Karyopharm Therapeutics’ earnings, with the highest sales estimate coming in at $300,000.00 and the lowest estimate coming in at $50,000.00. Karyopharm Therapeutics reported sales of $19.89 million in the same quarter last year, which would suggest a negative year-over-year growth rate of 99.3%. The company is scheduled to issue its next earnings results on Tuesday, August 6th.
On average, analysts expect that Karyopharm Therapeutics will report full-year sales of $6.78 million for the current financial year, with estimates ranging from $1.50 million to $15.20 million. For the next fiscal year, analysts anticipate that the company will post sales of $53.95 million, with estimates ranging from $20.40 million to $102.09 million. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Karyopharm Therapeutics.
Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Thursday, May 9th. The company reported ($1.09) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.84) by ($0.25). The business had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.75 million. Karyopharm Therapeutics had a negative return on equity of 119.66% and a negative net margin of 1,005.85%.
Karyopharm Therapeutics stock traded down $0.03 during mid-day trading on Friday, hitting $7.88. The company’s stock had a trading volume of 1,116,221 shares, compared to its average volume of 1,841,892. The company has a quick ratio of 6.19, a current ratio of 6.19 and a debt-to-equity ratio of 0.98. The firm has a market capitalization of $511.26 million, a PE ratio of -2.51 and a beta of 2.43. Karyopharm Therapeutics has a twelve month low of $3.92 and a twelve month high of $21.71. The firm’s fifty day simple moving average is $6.56.
Institutional investors have recently bought and sold shares of the stock. Two Sigma Investments LP boosted its stake in Karyopharm Therapeutics by 53.2% in the 4th quarter. Two Sigma Investments LP now owns 611,153 shares of the company’s stock worth $5,727,000 after purchasing an additional 212,196 shares during the period. FMR LLC boosted its stake in shares of Karyopharm Therapeutics by 51.5% during the 4th quarter. FMR LLC now owns 1,875,140 shares of the company’s stock valued at $17,570,000 after buying an additional 637,357 shares during the period. Deutsche Bank AG boosted its stake in shares of Karyopharm Therapeutics by 79.1% during the 4th quarter. Deutsche Bank AG now owns 479,323 shares of the company’s stock valued at $4,489,000 after buying an additional 211,764 shares during the period. Premier Asset Management LLC acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter valued at $282,000. Finally, First Midwest Bank Trust Division boosted its stake in shares of Karyopharm Therapeutics by 259.2% during the 1st quarter. First Midwest Bank Trust Division now owns 610,850 shares of the company’s stock valued at $3,567,000 after buying an additional 440,769 shares during the period. 84.20% of the stock is owned by hedge funds and other institutional investors.
Karyopharm Therapeutics Company Profile
Karyopharm Therapeutics Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Its lead drug candidate is Selinexor(KPT-330), which is in Phase IIb clinical study in treatments of refractory multiple myeloma; Phase Ib/II clinical study in combination with backbone treatments for multiple myeloma patients; Phase III clinical trial in combination with Velcade (bortezomib) and dexamethasone for multiple myeloma patients; Phase IIb clinical study in diffuse large B-cell lymphoma; Phase II/III clinical study in liposarcoma; Phase III clinical trial in endometrial cancer; and Phase II clinical trial in glioblastoma multiforme.
Further Reading: Diversification
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.